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of all skin cancers, metastatic melanoma is the deadliest form. Early diagnosis allows it to be cured with surgery alone; later presentations considerably limit successful treatment 
options. Dr Nicholas Refalo, Consultant Oncologist at Mater Dei 
Hospital, explains to Dr Gabriel Ellul the toll which metastatic 
melanoma has on the Maltese population, and the current 
treatment options available.
ts: what is mEtastatic mElaNoma?
Melanoma is the malignant proliferation of melanocytes. 
As in all malignant growths, it is classified into stages 
depending on its degree of spread. Metastatic melanoma 
relates to stage IV of the disease, with metastatic spread 
to multiple organs, most notably lungs, liver, brain and 
bone. Spread occurs primarily via the lymphatic system, 
with haematogenous spread either arising secondary to the 
lymphatic dissemination of the tumour, or else once the 
tumour directly invades the vascular system.
A distinguishing and morbid aspect of stage IV melanoma 
is its poor survival rate with the 10-year survival rate being, at 
best, less than 10%. At this advanced stage of disease, the role of 
surgery and radiation is limited, and the only viable options are 
systemic treatment modalities.
ts: what causEs thE disEasE?
The aetiology of melanoma is a widely studied subject, 
with the principal causative factors being exposure to UV light 
and a genetic predisposition, amongst others. Additionally, 
there are a multitude of risk factors which decrease the overall 
survival rate, including older age, poor performance status at 
time of diagnosis, male gender, multiple metastatic sites, shorter 
disease-free intervals, leukocytosis, and neutrophilia prior to 
initiation of treatment.
Melanoma, in its aetiology, may arise from a number 
of different sites, with this forming the basis in the genetic 
variability of melanoma. Four distinct genetic types have in fact 
been identified: melanoma arising from normal skin without 
any preceding sun exposure; that arising from skin which had 
undergone chronic exposure to UV irradiation; melanoma 
arising from the soles of feet or the palms of the hands; and 
melanoma derived from mucosal surfaces.
This distinction has served to direct certain gene-based 
treatment modalities.
ts: how doEs advaNcEd mElaNoma maNiFEst itsElF aNd how 
commoN is it?
These patients usually present with multi-organ involvement, 
mostly with metastases to the lungs, liver, brain and bone. 
Locally, metastatic melanoma accounts for up to 10 new cases a 
year. They are usually referred with curative intent, but current 
treatment options provided by the public health care system 
allow only palliation at the very best.
ts: how so? which trEatmENts arE availablE locallY?
Locally we make use of dacarbazine, an alkylating agent 
approved by the FDA in 1975 - more than 4 decades ago. 
Patients on this drug only have a one-in-eight chance of 
tumour shrinkage.1 In fact, an analysis of a total of 23 RCTs 
concluded that the objective response rate for monotherapy with 
dacarbazine hovers around 15%.2
Furthermore, responses are rarely sustained, with fewer 
than 2% of patients with metastatic melanoma, treated with 
dacarbazine, surviving for more than 6 years.3 Consequently, the 
primary purpose of dacarbazine is palliation, not treatment, of 
metastatic melanoma.
Despite these shortcomings, dacarbazine remains the only 
form of chemotherapy funded by our healthcare system here in 
Malta. All other options, available abroad, require private funding.
ts: how doEs this comParE to currENt staNdards oF carE?
In view of the poor survival rates with the available 
chemotherapeutic modalities, as evidenced by data supporting 
dacarbazine, there has been a shift towards immune-mediated 
therapies and targeted therapies in Europe.
Over the past decade, with an enriched understanding of the 
pathogenesis of melanoma, novel therapies have been adopted in 
a multitude of European countries, which have had a profound 
impact on the survival rates of patients with metastatic melanoma.
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These most notably include a drug called ipilimumab, 
an immunomodulator targeting the function of cytotoxic 
T-lymphocyte associated antigen-4 (CTLA-4).
Activated T-lymphocytes express this antigen, which in turn 
hinders positive stimulatory signals directed towards them. 
Thus, CTLA-4 acts negatively, to inhibit T-cell activation in the 
healthy individual.
Ipilimumab acts against CTLA-4. As a monoclonal antibody, 
it inhibits it and thus obtunds its inhibitory effect on T-cell 
activation, thereby indirectly prompting the T-cell mediated 
immune system to counter cancer more effectively.
Response rates to ipilimumab are encouraging. A phase III 
trial on previously treated, unresectable advanced melanoma 
showed an overall rate of survival of 45.6% after 12 months of 
therapy, and 23.5% after 24 months of ipilimumab monotherapy. 
Such trials also compared the efficacy of this monoclonal antibody 
when given in combination with vaccination strategies, producing 
even more favourable results.4
These results have prompted the FDA to expedite its 
approval of ipilimumab as a treatment modality for metastatic 
melanoma in March 2011, after more than a decade without any 
pharmaceutical innovation in the field.
The response rates to dacarbazine pale in comparison to the 
results achieved through this novel treatment.
And while these results are encouraging, the same can be 
said to another treatment strategy which is currently being given 
much attention through research and clinical trials. As outlined 
previously, melanoma has been classified into four distinct genetic 
subtypes. Of those melanomas developing from normal skin, 
like the thighs and trunk, which has not been exposed to chronic 
insolation, around 60% have a mutation in the B-RAF gene.
The B-RAF gene acts as a proto-oncogene, with gain-of-
function mutations allowing it to promote cell growth and 
division unchecked. The rationale behind targeted therapies is to 
shut down these genes, thereby annulling their positive effect on 
tumour growth.
The results obtained with such an approach are astounding: 
major shrinkage of advanced melanoma tumours was obtained 
through the use of a drug called PLX4032, with positive response 
rate in over 80% of treated patients.5 And while most of these patients 
eventually suffered from melanoma recurrences, prompting the need 
for future studies of possible combination therapies making use of 
this novel drug, the results speak for themselves.
Similar approaches are also being adopted for the different 
genetic subtypes, with ongoing research on potential inhibitors 
of the KIT proto-oncogene, which also plays a significant role in 
the aetiology of advanced melanoma.
ts: what arE Your viEws about thE diFFErENcE iN rEsPoNsE aNd 
survival ratEs bEtwEEN thEsE NovEl thEraPiEs aNd thE oNEs oN 
thE govErNmENt FormularY?
To this day, dacarbazine remains the only systemic therapy 
available for advanced melanoma patients on the government 
formulary. And as discussed previously, the response rates for 
dacarbazine do not, in any way, match those obtained through 
the novel treatments available today.
As things stand, I feel confronted with the difficult 
situation of informing my patients that the only available 
“cure” afforded to them through the public health system is 
one which has nowadays been all but superseded by drugs 
which are not part of the formulary. The best I can offer 
them, presently, is dacarbazine, a drug which is palliative and 
not curative. 
The price for immunotherapy or targeted therapy ranges 
in the tens of thousands of euro a month, with an estimated 
yearly cost of more than €120,000 for 12 months of therapy, 
despite discounts by the local pharmaceutical companies.
We are currently in a situation where advanced melanoma 
patients in Malta, who have a modest level of income, cannot 
afford basic curative treatment, which is otherwise available in 
other European countries.
Oncological centres across Europe, from well-established 
centres in Western Europe to less developed countries such as 
Albania, have made the necessary shift: they are treating their 
patients with these novel drugs for advanced melanoma, thus 
affording them a better chance of recovery.
ts: what arE Your coNcludiNg rEmarKs?
The situation is in a dire need for change.
In the present state of affairs, all Maltese patients diagnosed 
with advanced melanoma have only two options: either buy 
this costly medication or else ask for help from local charitable 
institutions.
The former is a viable alternative only to those who are 
insured or else have the necessary financial means. With 
regards to the latter option, we cannot constantly rely on 
charity to provide for the needs of these patients. If these two 
options fail, the chances of successful recovery from advanced 
melanoma remain very, very slim.
The annual incidence rates of advanced melanoma may 
not be as high as in other, more well-known forms of cancer. 
However, we have a duty to each of our patients.
I believe that this situation warrants more public exposure; 
there is a need for greater public advocacy on the issue. That is 
why I have decided to speak up. 
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